Back |
home / stock / reta / reta message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: RETA 23% v2,7M c102.63 f36,2M H103 | znewcar1 | investorshangout | 05/20/2021 3:08:46 AM |
Bought in at 85.00 im looking good | ahimsa27 | investorshub | 04/19/2021 1:13:53 PM |
znewcar1: RETA 32% v1,3M c174.66 f33,6M H.175.52 EOD push | znewcar1 | investorshangout | 11/09/2020 10:45:04 PM |
Ladenburg Thalmann Financial Services is a German Company | Plegee | investorshub | 02/15/2020 12:43:40 PM |
Saw this on another board, do not recognize | Plegee | investorshub | 02/14/2020 10:53:41 PM |
Great future here in my opinion $RETA | Cbdpotential | investorshub | 11/21/2019 12:37:15 PM |
Phase 3 Cardinal Successful Outcome | Plegee | investorshub | 11/11/2019 11:36:53 PM |
$CEO just on CNBC discussing recent trial data | Whalatane | investorshub | 10/18/2019 6:48:40 PM |
Thankya! :-) | Cbdpotential | investorshub | 10/16/2019 9:38:57 PM |
Congrats ... you have been in $RETA for | Whalatane | investorshub | 10/16/2019 7:24:05 PM |
$RETA Reata Pharma ($RETA) announces registrational Part 2 | $Pistol Pete$ | investorshub | 10/16/2019 1:02:23 AM |
I think we hit 200 tomorrow or thursday | rynlrt | investorshub | 10/15/2019 7:13:40 PM |
Still looking great! $RETA | Cbdpotential | investorshub | 10/15/2019 5:23:56 PM |
New share price target by Jefferies raised to $254 | rynlrt | investorshub | 10/15/2019 2:51:42 PM |
Im in for a small position in the $130s | T695 | investorshub | 10/15/2019 2:15:27 PM |
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...